VEGFA and neoplasm: Lower-dose antiangiogenic treatment (anti-VEGF therapy) could normalize breast tumor vasculature and change the tumor microenvironment from being immunosuppressive to immunosupportive, thereby improving the efficacy of immunotherapies (90).